John A. Blessing

Medicine · Health Sciences

70h-index17.6kcitations301works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(172), Endometrial and Cervical Cancer Treatments(116), Uterine Myomas and Treatments(50), Colorectal and Anal Carcinomas(35), Cervical Cancer and HPV Research(30)

Publications301 total

Twilight of Democratic Consolidation
2019
Law and the Supernatural: A Transition of Modernity in Britain, 1650-1850
2019
Syrian Refugees: Boon or Bust?
2018
Adjuvant Chemotherapy in High-Risk Endometrial Carcinoma1
2015
Chemotherapy in Advanced or Recurrent Endometrial Carcinoma1
2015
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology·2014· 17 citedOpen Access
Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group
Journal of Clinical Oncology·2014· 20 citedOpen Access
Gynecologic oncology group strategies to improve timeliness of publication
Clinical Trials·2013· 5 cited
GOG0076-GG: A limited access phase II trial of pemetrexed (LY231514) (NSC #698037) in combination with cisplatin (NSC #119875) in the treatment of advanced, persistent, or recurrent carcinoma of the cervix—A Gynecologic Oncology Group study.
Journal of Clinical Oncology·2013· 1 cited
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
Gynecologic Oncology·2012· 70 citedOpen Access
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
Gynecologic Oncology·2012· 96 cited
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study
Gynecologic Oncology·2011· 92 citedOpen Access
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
Gynecologic Oncology·2010· 41 cited
A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial
International Journal of Gynecological Cancer·2010· 16 citedOpen Access
Gynecologic Oncology Group quality assurance audits: analysis and initiatives for improvement
Clinical Trials·2010· 3 cited
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study
Gynecologic Oncology·2010· 32 cited
Erratum
Gynäkologische Rundschau·2009Open Access
Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Journal of Clinical Oncology·2009· 70 citedOpen Access
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology
Gynecologic Oncology·2009· 34 cited
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A Gynecologic Oncology Group study
Gynecologic Oncology·2009· 29 cited
page 1 of 16Next →

Frequent Co-authors

William T. Creasman(13), Philip J. DiSaia(9), Peter G. Rose(7), Howard D. Homesley(7), J.T. Thigpen(6), Gregory P. Sutton(6), Hugh M. Shingleton(5), Francis J. Major(4), Edgardo Yordan(4), David H. Moore(4), Robert S. Mannel(4), Kenneth D. Hatch(4), Clarence E. Ehrlich(3), Jackson B. Beecham(3), Koen DeGeest(3), Leo D. Lagasse(3), Richard C. Boronow(3), John H. Malfetano(3), Steven G. Silverberg(2), C. Paul Morrow(2)